



Elekta Unity to become cornerstone of Moffitt Cancer Center's MRgRT program

TAMPA – Elekta (EKTA-B.ST) announced today that it will collaborate with <u>Moffitt Cancer</u> <u>Center</u>, a National Cancer Institute-designated comprehensive cancer center, to grow their MR-guided adaptive radiation therapy (MRgRT) program around the Elekta Unity MR-Linac.

High field MRgRT is an innovative treatment option that provides clinical teams with exceptional clarity of the tumor and nearby soft tissue anatomy both before and in real-time during treatment. This real-time visualization enables doctors to adapt the treatment to precisely target the patient's cancer, aiming to improve outcomes, reduce side effects and the number of treatment sessions required.

"Our center is focused on providing personalized radiotherapy using the most advanced technology," says <u>Dr. Kosj Yamoah</u>, chair of Moffitt's <u>Radiation Oncology Program</u>. "The MR-Linac technology enables adaptive beam delivery to high doses with unprecedented accuracy directed at specific disease sites, minimizing exposure to normal cells and lessening side effects."

Elekta Unity is the world's first and only high-field MR-Linac platform, offering anatomy-specific MR imaging and Comprehensive Motion Management. With the advanced system, clinicians can be certain they are accurately hitting the tumor target and sparing healthy tissue, even when the target moves.

"We are thrilled to welcome Moffitt Cancer Center, not only as long-time MOSAIQ users but also as a site with extensive MRgRT expertise, to our global community of Unity users," says Ardie Ermers, Elekta's Executive Vice President, Region Americas. "We eagerly anticipate the valuable insights and vast knowledge their team of researchers will bring to the MR-Linac Consortium's lung Tumor Site Group, particularly their experience in treating challenging, high-risk lung lesions with high-dose radiation from their impressive work across disease sites."

"Elekta Unity is a really exciting tool we will be able to utilize to take care of our cancer patients in a brand new way," says <u>Dr. Stephen Rosenberg</u>, Director of Adaptive Radiotherapy at Moffitt. "With this high field MRI scan and Comprehensive Motion Management, this system has a higher signal to noise ratio to better visualize tumors, track targets in real time, and allow focused radiotherapy to difficult-to-treat sites. That allows us to decrease our treatment volumes and spare normal organs, normal tissues, and hopefully decrease side effects as well. That's critical for patients who have lungs that might be compromised or have other normal organs that we're trying to spare with treatment."

In addition to Elekta Unity, the agreement includes software, including Elekta ONE | OIS, powered by MOSAIQ and Elekta ONE | Planning, as well as service.

Learn more about Elekta's MR-Linac technology at elekta.com/Unity.

###



For further information, please contact:

Mattias Thorsson, Vice President, Head of Corporate Communications

Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com

Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations

Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com

Time zone: ET: Eastern Time

About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com.

About Moffitt Cancer Center

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-833-365-2672), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.